Abstract: INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).

Content Format:

PDF

Credit Type:

--

Credits:

--
Slides: INTEGRATE IIa: Randomised double-blind Phase III  study of regorafenib versus placebo in refractory  advanced Gastro-Oesophageal Cancer (AGOC).

Content Format:

Slideset

Credit Type:

--

Credits:

--